Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8175707 | 0.98 | SIGMAR1 (0.60) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL29060516 | 0.86 | OPRM1 (0.59) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2267707 | 0.85 | SIGMAR1 (0.54) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4702868 | 0.82 | SIGMAR1 (0.51) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL28994161 | 0.82 | OPRM1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL27625085 | 0.82 | OPRM1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1660350 | 0.82 | SIGMAR1 (0.62) | SIGMAR1OPRM1DRD2HTR2C | |
| SCHEMBL8222575 | 0.81 | SIGMAR1 (0.57) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL10007651 | 0.80 | SIGMAR1 (0.61) | SIGMAR1OPRM1DRD2HTR2C | |
| SCHEMBL5349864 | 0.80 | OPRM1 (0.54) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
| US-6071932-A | SUPPRESSING ABSORPTION OF GAMMA-AMINOBUTYRIC ACID FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | BRITISH TECHNOLOGY GROUP INTERCORPORATE LICENSING LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0823905-A1 | NOVEL HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034863-A1 | NOVEL HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1996-11-07 | — | — | WO | disclosed |
| EP-0062873-A1 | 1-Substituted-4-phenyl-polyhydro-pyridines and -pyrrolidines, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1982-10-20 | — | — | EP | disclosed |
| US-4340597-A | 1-Substituted-4-aryl-1,2,5,6-tetrahydro and hexahydropyridines | SCHERING CORPORATION (US) | 1982-07-20 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
| US-RE28973-E | PARKINSON'S DISEASE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | SIGMAR1 244/4885OPRM1 189/4885OPRD1 173/4885 |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | SIGMAR1 3731/4885OPRM1 3770/4885OPRD1 3666/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SIGMAR1 1460/4885OPRM1 742/4885OPRD1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.